Komori
Kidswell Bio (4584) · InitiativeRestated

Development of New Biosimilars through a Capital and Business Alliance with ITOCHU Chemical Frontier

First written in FY2017. 5 of 6 entries say "Restated". Latest entry: FY2019.

6entries
3years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2017 – FY20192017: 220172018: 320182019: 12019
Same theme, other companies
Joint Development and Commercialization of BiosimilarsA theme 2 companies write about · 0 as a headwind · 6 as a tailwind

0 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2019RestatedAnnual report

    「In March 2017, we formed a capital and business alliance with Itochu Chemical Frontier Co., Ltd. for the development of new biosimilars and focused on advancing development.」

    The company continues its development partnership with Itochu Chemical Frontier for new biosimilars.
  2. FY2019-Q1RestatedAnnual report

    「Furthermore, in March 2017, the company entered into a capital and business alliance with Itochu Chemical Frontier Co., Ltd. for the development of new biosimilars.」

    The capital and business alliance with Itochu Chemical Frontier for new biosimilar development is being reiterated as an ongoing development activity.
  3. FY2018RestatedAnnual report

    「In March 2017, we formed a capital and business alliance with Itochu Chemical Frontier Co., Ltd. for the development of new biosimilars and focused on advancing development.」

    The capital and business alliance with Itochu Chemical Frontier for new biosimilar development is being reiterated as an ongoing development activity.
  4. FY2018-Q3RestatedAnnual report

    「In addition, we focused on development, including by forming a capital and business alliance with Itochu Chemical Frontier Co., Ltd. in March 2017 for the development of new biosimilars.」

    The capital and business alliance with Itochu Chemical Frontier for new biosimilar development is being reiterated as an ongoing development activity.
  5. FY2018-Q2RestatedAnnual report

    「In addition, we focused on development, including by forming a capital and business alliance with Itochu Chemical Frontier Co., Ltd. in March 2017 for the development of new biosimilars.」

    The capital and business alliance with Itochu Chemical Frontier for new biosimilar development is being reiterated as an ongoing development activity.
  6. FY2017First statedAnnual report

    「In March 2017, we formed a capital and business alliance with Itochu Chemical Frontier Co., Ltd. for the development of new biosimilars.」

    The capital and business alliance with Itochu Chemical Frontier marked the first appearance of a theme involving the development of new biosimilars.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Kidswell Bio yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.